Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants
The DOI matches its Crossref record.
Abstract
Little is known concerning possible hazards of maternal use of the recently introduced antidepressant drugs with noradrenergic and varying serotonergic activity (serotonin-noradrenaline reuptake inhibitor [SNRI]/noradrenergic reuptake inhibitor [NRI] drugs). Using the Swedish Medical Birth Registry, we identified 732 women who had used SNRI/NRI drugs in early pregnancy. Maternal characteristics were studied as well as delivery outcome: pregnancy duration, birth weight, neonatal diagnoses, infant deaths, and congenital malformations. Comparisons were made with all deliveries in the population (n = 860,215) after adjustment for identified confounders, and risks were expressed as odds ratios or (when numbers were low) as risk ratios. Women using SNRI/NRI deviated from other women by being older, more often having their first infant, being more extensive smokers, having a higher body mass index, and more often being born within Sweden. These characteristics, like the pattern of concomitant drug use, resembled much those of women using selective serotonin reuptake inhibitor (SSRI) drugs. The rate of preterm births was significantly increased (odds ratio, 1.6; 95% confidence interval, 1.19-2.15), and neonatal symptoms such as respiratory problems, low Apgar score, hypoglycemia, and neonatal convulsions showed a similar pattern as seen after maternal SSRI treatment. We found no increased risk for stillbirths or congenital malformations. Delivery outcome after exposure to SNRI/NRI drugs resembles much what has been described after use of SSRI drugs. No signs of teratogenicity were found.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Yonkers, K. A., Wisner, K. L., Stewart, D. E., Oberlander, T. F., Dell, D. L., Stotland, N., Ramin, S., Chaudron, L., & Lockwood, C. (2009) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2009.04.003 · Cited by 469
(2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181ba0632 · Cited by 345
Depression during pregnancy and postpartum
Becker, M., Weinberger, T., Chandy, A., & Schmukler, S. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0664-7 · Cited by 263
Huang, H., Coleman, S., Bridge, J. A., Yonkers, K., & Katon, W. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2013.08.002 · Cited by 180
Antidepressant use in pregnancy: a critical review focused on risks and controversies
Byatt, N., Deligiannidis, K. M., & Freeman, M. P. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12042 · Cited by 158
“While the available evidence is extremely limited, studies examining venlafaxine, duloxetine, nefazodone, and mirtazapine do not suggest an increased risk of congenital malformations (32, 39, 81, 89, 90).”
BackgroundAntidepressants in pregnancy: a systematic review.
(2010) · PubMed · doi:10.3109/00048674.2010.507543 · Cited by 128
Prevalence of Antidepressant Use during Pregnancy in Denmark, a Nation-Wide Cohort Study
Jimenez-Solem, E., Andersen, J. T., Petersen, M., Broedbaek, K., Andersen, N. L., Torp-Pedersen, C., & Poulsen, H. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063034 · Cited by 119
“However, the results are conflicting [12,14,17–19,23–33] and studies including up to a million pregnancies indicate little risk of congenital malformations [12], [17,19,31,32], or the possibility of confounding by indication [34].”
ResultCalderon-Margalit, R., Qiu, C., Ornoy, A., Siscovick, D. S., & Williams, M. A. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.06.061 · Cited by 115
Tuccori, M., Testi, A., Antonioli, L., Fornai, M., Montagnani, S., Ghisu, N., Colucci, R., Corona, T., Blandizzi, C., & Tacca, M. D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.07.009 · Cited by 95
Drug treatment for mood disorders in pregnancy
Gentile, S. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283413451 · Cited by 60
Adverse reactions to duloxetine in depression
Bitter, I., Filipovits, D., & Czobor, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.582037 · Cited by 38
“15), and neonatal symptoms pattern similar to that seen after maternal SSRI treatment [101].”
BackgroundPregnancy Outcome Following Maternal Exposure to Mirtazapine: A Multicenter, Prospective Study
Winterfeld, U., Klinger, G., Panchaud, A., Stephens, S., Arnon, J., Malm, H., te Winkel, B., Clementi, M., Pistelli, A., Maňáková, E., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000309 · Cited by 34
“An increased risk for preterm delivery after mirtazapine exposure was previously reported.(20,22) However, the rates of preterm deliveries observed in our study did not differ significantly, and gestational age at birth and birth weight were similar in the 3 groups, despite a higher proportion of women in the mirtazap…”
ResultTak, C. R., Job, K. M., Schoen-Gentry, K., Campbell, S. C., Carroll, P., Costantine, M., Brixner, D., Birnbaum, A. K., & Sherwin, C. M. T. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2269-4 · Cited by 27
Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20166565 · Cited by 17
“, 2007 [46] Retrospective cohort study SSRI, SNRI, NRI Significant respiratory problems risk for SSRI early exposure (OR = 1.”
BackgroundResultInfluential
Metadata
- Authors
- Lennestål, R., & Källén, B.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-12
- Volume
- 27
- Issue
- 6
- Pages
- 607-613
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1975558262
- Cited by
- 129
- References
- 0
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.